Concerns are mounting that Australia pharmaceutical tariffs impact could be significant, as the country’s billion-dollar pharmaceutical export industry may become the next target in U.S. President Donald Trump’s escalating tariff war.
This follows the Trump administration’s recent confirmation of a 25% tariff on steel and aluminium imports, despite hopes that Australia would be granted an exemption.
The medicines rate could go up nationwide and shake the pharmaceuticals due to the potential increased tariffs.
Currently, Australia is a major supplier of pharmaceutical products, and with any potential interference in trade with the U.S. could have adverse effects on both industries and consumers.
As per the experts, if tariffs extend to the pharmaceutical sector, it may not only hurt Australian manufacturers but also increase prices for local patients relying on imported medications, further emphasising the Australia pharmaceutical tariffs impact on the healthcare system.
Prime Minister Anthony Albanese has strongly opposed Trump’s tariff moves. He remarked the move “unjustified” and “self-damaging” to the U.S. economy.
Despite the pressure, he has made it clear that Australia will not retaliate with its own trade restrictions.
There are now mounting concerns that Australia’s pharmaceutical exports to the U.S., valued at around $1.1 billion in 2024, could be the next target.
Being the major supplier in the pharmaceutical sector, any shake-up due to the increase in tariffs could have serious consequences.
The country could bear the burden if tariffs are implemented, given the ongoing whopping $18 billion federal government program designed to make medicines more affordable.
Since the tariff war is looming and if enforced by the U.S. Government, essential medicine prices will skyrocket for the general public who rely on these medications and the government.
Over the years, several U.S. companies have voiced against the Australia’s medicine subsidy scheme, which helps to lower the medicine prices and severely affecting the profits that these companies try to make.
And now since the U.S. government have started to impose tariffs, these companies could get the chance to boost their earnings by compromising the Pharmaceutical Benefits Scheme (PBS).
“Health always remains the main subject in the country and it shouldn’t be affected, given there is a scheme that helps lowering the medicine prices, and it shouldn’t be bargained in a trade dispute with the Trump administration”, said Consumers Health Forum of Australia chief Elizabeth Deveny in an interview with the Sydney Morning Herald.
“We all are thriving and making the country great by maintaining our health. The country can’t afford to compensate with any trade dispute”.
“Australians have history to stick to the country’s healthcare system and with any dispute, they don’t want to change the path and rely on US-style healthcare”.
The major PBS helped country in reducing the medicines cost and over 930 medications are made affordable over the last financial year.
The on-going tariff war by the U.S. government has already shaken the several countries including Australia and President Trump continues to put pressure.
Trump has previously pointed out the reason for the high cost of medicines in the U.S. and, upon joining his first term as president, he called out several countries as a reason for the increased cost.
Besides, he also claimed that several countries benefit from America’s large investment in medical research without contributing enough in return.
